Alexion has teamed up with Dicerna to branch out into RNAi therapies for complement-mediated diseases. The deal gives Alexion the rights to two preclinical assets, plus an option on two more, in ...

The stock market’s behavior might appear baffling at times, but when you see shares of a biotech sinking, the reason is almost always one of two ready-made options: regulatory rejection or ...

Investors are happy the biotech ended a lawsuit hanging over its head. Both companies are developing RNA interference drugs that seek to knock down protein levels by targeting RNA, which is the ...

Dicerna and Alynylam, which sued each other over trade secrets relating to RNAi technology, are burying the hatchet just days ahead of their court date. The former will fork over $2 million and ...

— Company Achieves Multiple Clinical and Corporate Development Milestones in 2019, Advancing Core Pipeline Candidates; Expanding and Progressing Existing Collaborative Programs; and Establishing New, ...

– Dicerna To Receive $180 Million Upfront and Up to $60 Million in Potential Additional Milestone Payments – “We are delighted to accomplish this transaction with Dicerna, an emerging leading player ...

Investing.com — Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) shares have opened 78% above Wednesday's close after the company said it has agreed to be acquired by Danish drug maker Novo Nordisk A/S (NYSE ...

Carillon Tower Advisers, an investment management firm, published its “Carillon Eagle Small Cap Growth Fund” third quarter 2021 investor letter – a copy of which can be downloaded here. Small-cap ...

Ribonucleic acid (RNA) serves several critical cellular functions, acting as a messenger between DNA and ribosomes where proteins are made, forming vital portions of the ribosomes themselves and ...

Two of Greater Boston's longtime biotech rivals, Dicerna Pharmaceuticals Inc. and Alnylam Pharmaceuticals, may have resolved their legal fights, but a battle for market dominance looms in 2020.

Investors ponder the biotech's secondary offering. Of course, shares were down 18% yesterday after Dicerna let investors know it planned to sell more shares, so today's jump is likely just a sign that ...

Shares of newly public Dicerna Pharmaceuticals Inc. barreled up nearly 207 percent in their first day of trading Thursday, giving the Watertown biotechnology startup the largest opening-day gain of ...